In the space of a single week, three doula-focused maternal health startups announced a combined $27 million in new funding. Nadia Care raised $12 million, Malama Health raised $9.2 million, and Flourish Care raised $5.7 million. All three are building for Medicaid populations. All three are reporting hard outcomes data. And all three are scaling models that look less like wellness services and more like clinical care delivery.
That concentration of capital into a single care model, for a single payer segment, in a single week, doesn't seem to be just coincidence. It’s a signal that doula care is transitioning from a nice-to-have into reimbursable healthcare infrastructure - and that the economics of prevention in maternal health are starting to attract serious investment.
First: What Is a Doula & How Does It Fit Into Maternal Care?
Generally speaking a doula is a trained, non-clinical professional who provides continuous physical, emotional, and informational support throughout pregnancy, labor, delivery, and the postpartum period. They are not doctors. They are not midwives. They do not perform clinical procedures or deliver babies.
The distinction matters. An OB-GYN manages the medical safety of a pregnancy and delivery. A midwife can manage low-risk births and provide clinical care. A labor and delivery nurse manages hospital protocols and monitors multiple patients simultaneously. A doula’s role is different from all of these: They are the only provider whose entire job is continuous, one-on-one support for the mother. They help with birth planning, pain management, breastfeeding, emotional support, and - increasingly - navigation of a healthcare system that many women, particularly those on Medicaid, find difficult to access and trust.
The evidence base for doula care is substantial. Research consistently shows that continuous support during labor reduces C-section rates, lowers preterm birth rates, decreases NICU admissions, and improves breastfeeding outcomes. A study published in the American Journal of Public Health found that Medicaid-enrolled women who used a doula faced a 47% lower risk of C-section and a 29% lower risk of preterm birth.
Why Now: The Medicaid Shift
For most of its history, doula care was a private-pay service - putting it out of reach for the women who need it most. Medicaid covers more than 40% of all U.S. births, and the populations it serves - disproportionately Black, Indigenous, and low-income women - face the worst maternal outcomes in the U.S. The country has the highest maternal mortality rate among high-income nations, with a rate roughly triple that of the UK, France, or Japan. For Black women, it’s even higher - approximately 50 deaths per 100,000 live births. And over 80% of these deaths are preventable.
The scale of this crisis has driven a significant policy shift. As of mid-2025, 46 states and Washington D.C. had taken steps toward Medicaid coverage for doula services, with more than 30 states actively reimbursing or implementing laws to do so. Reimbursement rates range from $450 to $3,500 per birth, with Washington state recently setting the highest rate in the country. This has bipartisan support - Republican-controlled legislatures in Arkansas, Utah, Louisiana, and Montana have all passed doula reimbursement legislation since the start of 2025.
This policy momentum is the foundation all three raises are built on. The market for doula care is no longer limited to women who can pay out of pocket. It now has a payer - and that payer has a strong financial incentive to fund it, because the alternative is far more expensive (more on that later).
Three Companies, Three Models, One Thesis
While all three startups,who recently raised share the core thesis that doula care can improve outcomes and lower costs within Medicaid, they are building slightly different models.
Nadia Care (formerly Cayaba Care) raised $12 million led by Valtruis and a major national payer. The company deploys multidisciplinary teams - Maternity Navigators, registered nurses, doulas, and lactation consultants - to provide in-home and virtual support alongside existing providers. It currently operates in Washington D.C., Maryland, and Tennessee, partnering with large regional Medicaid plans. The outcomes data from approximately 4,000 members is notable: A 60% reduction in NICU days, 47% reduction in low birth weight rates, 38% lower preterm birth rates, and 25% fewer emergency room visits.
Malama Health raised $9.2 million in seed funding led by Acumen America, with a capital stack that includes a $2.3 million NIH grant and $900,000 in California state funding - reflecting alignment across federal, state, and private investors. Malama employs Doula-Care Navigators who attend births, conduct home visits, and stay with women through the full postpartum year. From more than 2,500 women served, the company reports a 38% decrease in preterm birth rates, a 9% decrease in C-section rates, and a 6% decrease in NICU admissions. A randomized controlled trial at Tufts Medical Center found women who used Malama were 40% less likely to develop postpartum diabetes - a result that speaks directly to the postpartum gap (more on that below).
Flourish Care raised $5.7 million in seed funding led by Zeal Capital Partners. The company operates as a doula matching network across 18 states, pairing patients with doulas based on cultural preferences, language, and location. Flourish recently went in-network with UnitedHealthcare - a significant commercial payer milestone - while continuing to serve primarily Medicaid populations. The company is also investing in a data platform to risk-stratify patients and intervene earlier, positioning itself as a technology-enabled care coordination layer.
The Postpartum Gap
One of the most important and underappreciated aspects of the doula model is what happens after delivery. In the U.S., roughly two-thirds of maternal deaths occur during the postpartum period - from one day to a full year after giving birth. Yet the standard postpartum follow-up in the American healthcare system is a single visit at six weeks. Many women, particularly those on Medicaid, never make it to that appointment.
This is where the doula model diverges most sharply from conventional maternal care. All three companies provide support that extends well beyond labor and delivery. Malama’s navigators stay with women for a full year postpartum. Flourish’s program runs from 12 weeks pregnant to 12 months postpartum. Nadia Care provides in-home care coordination, lactation support, nutrition counseling, and prenatal and new parent education.
The postpartum period is when many of the most dangerous complications - hemorrhage, hypertensive disorders, cardiomyopathy, infection, postpartum depression - go undetected because women simply fall out of the system. A doula who is in regular contact with a new mother, tracking blood pressure and glucose readings and escalating clinical signals in real time, fills a gap that the existing appointment-based model does not.
The Economics: Why Medicaid Is Paying Attention
The business case is straightforward. A single NICU stay can cost a Medicaid plan hundreds of thousands of dollars. A preterm birth is significantly more expensive than a full-term delivery. An emergency C-section costs more than a vaginal birth. If a doula who costs a Medicaid plan a few thousand dollars per birth can reduce the incidence of any of these outcomes - and the data from all three companies suggests they can - the return on investment is clear.
This is why the funding sources are as interesting as the amounts. Nadia Care’s round was co-led by a major national payer - a signal that insurers are not just observing this model but actively investing in it. Malama’s round blends venture capital with NIH grants and state funding. Flourish is going in-network with UnitedHealthcare. The fact that payers, government agencies, and venture investors are all converging on the same model simultaneously suggests this is not a trend driven by enthusiasm alone. It’s being driven by economics.
What to Watch
Three raises in one week does not mean the model is proven at scale. Several open questions remain. Can these companies build and retain a doula workforce large enough to meet demand, particularly given that Medicaid reimbursement rates in many states still don’t reflect the full scope of doula work? Can the outcomes data hold up as they scale beyond their initial geographies? And what happens to state Medicaid programs amid ongoing uncertainty around federal funding?
But the direction is clear: The U.S. maternal health crisis is severe, measurable, and expensive. The doula model has evidence behind it, policy momentum beneath it, and now - with nearly $27 million in a single week - serious capital flowing into it.
It seems what started as a luxury service is now slowly but surely becoming an accessible standard of care.
